GlassScriptPhysician profile
Christopher Jon Mckay
NPI 1134696131
$2,473.75
in general payments reported to CMS, 2019-2025
20 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $302 · 2022: $843 · 2023: $638 · 2024: $407 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,329.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $695.31 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $463.82 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $353.40 | 2021-2025 | Jardiance |
| Abbvie INC. | $155.03 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $144.43 | 2021-2023 | Ajovy, Austedo Xr |
| Lilly USA, LLC | $142.82 | 2022-2024 | Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $120.48 | 2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $76.69 | 2022-2023 | |
| Edwards Lifesciences Corporation | $42.84 | 2025 | Sapien 3 Ultra Resilia |
| Eisai INC. | $37.66 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.50 | 2022-2023 | Trintellix |
| Antares Pharma, INC. | $34.11 | 2022-2023 | Nocdurna, Tlando, Xyosted |
| Biohaven Pharmaceuticals, INC. | $33.07 | 2021 | |
| Phathom Pharmaceuticals, INC. | $26.98 | 2025 | Voquezna |
| Collegium Pharmaceutical, INC. | $24.25 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $21.99 | 2024 | Cologuard Collection Kit |
| Tolmar, INC. | $17.97 | 2024 | |
| Idorsia Pharmaceuticals US INC | $17.42 | 2023 | Quviviq |
| Amarin Pharma, INC. | $16.71 | 2022 | |
| Pfizer INC. | $14.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mckay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.